Re­lay and iTeos join IPO del­uge while Ak­ou­os and Fu­sion de­cide they can earn more

They just don’t. Stop. Com­ing.

If biotechs have learned any­thing dur­ing the pan­dem­ic econ­o­my, it’s that in­vestors have be­come ea­ger to jump in to buy stock in drug­mak­ers. And a week af­ter we saw two ear­ly-stage US biotechs and a large South Ko­re­an bio­phar­ma fetch more than $1.2 bil­lion  — and two weeks af­ter we saw three biotechs raise $200 mil­lion-plus be­fore they en­tered the clin­ic — two more drug­mak­ers have de­cid­ed to go pub­lic and two oth­ers de­cid­ed they could raise mil­lions more than they had orig­i­nal­ly asked.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.